Blueprint to boost R&D for diseases of the developing world

A new study, commissioned by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), has been released reviewing initiatives to encourage research and development (R&D) for diseases such as HIV, tuberculosis, malaria and neglected tropical diseases.

The report, titled Assembling the pharmaceutical R&D puzzle for needs in the developing world, introduces a blueprint based on six enabling factors that comprise: identification of gaps in the R&D process, mitigation of risk and cost of R&D, ability to translate research into clinical outcomes, sustainability of funding for specific disease areas, effective access to new medicines, and compatibility with different R&D mechanisms.